Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type...

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2015 Oct 2

PMID 26426481

Citations 10

Authors

Pedro M Garcia-Barrantes

Hyekyung P Cho

Colleen M Niswender

Frank W Byers

Charles W Locuson

Anna L Blobaum

Zixiu Xiang

Jerri M Rook

P Jeffrey Conn

Craig W Lindsley

Affiliations

Soon will be listed here.

Abstract

The therapeutic potential of selective mGlu1 activation is vastly unexplored relative to the other group I mGlu receptor, mGlu5; therefore, our lab has focused considerable effort toward developing mGlu1 positive allosteric modulators (PAMs) suitable as in vivo proof of concept tool compounds. Optimization of a series of mGlu1 PAMs based on an N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide scaffold provided 17e, a potent (mGlu1 EC50 = 31.8 nM) and highly CNS penetrant (brain to plasma ratio (Kp) of 1.02) mGlu1 PAM tool compound, that potentiated not only wild-type human mGlu1 but also mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenic patients. Moreover, both electrophysiological and in vivo studies indicate the mGlu1 ago-PAMs/PAMs do not possess the same epileptiform adverse effect liability as mGlu5 ago-PAMs/PAMs and maintain temporal activity suggesting a broader therapeutic window.

Citing Articles

Further Optimization of the mGlu PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685.

Reed C, Kalbfleisch J, Turkett J, Trombley T, Spearing P, Haymer D ACS Chem Neurosci. 2025; 16(4):745-752.

PMID: 39907715 PMC: 11843613. DOI: 10.1021/acschemneuro.5c00014.

Discovery of VU6024578/BI02982816: An mGlu Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models.

Reed C, Kalbfleisch J, Turkett J, Trombley T, Nastase A, Spearing P J Med Chem. 2024; 67(24):22291-22312.

PMID: 39665415 PMC: 11684029. DOI: 10.1021/acs.jmedchem.4c02554.

Targeting Neuroplasticity in Substance Use Disorders: Implications for Therapeutics.

Wolf M Annu Rev Pharmacol Toxicol. 2024; 65(1):259-280.

PMID: 39374445 PMC: 11864087. DOI: 10.1146/annurev-pharmtox-061724-080548.

Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

Dogra S, Conn P Mol Pharmacol. 2022; 101(5):275-285.

PMID: 35246479 PMC: 9092465. DOI: 10.1124/molpharm.121.000460.

mGlu potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits.

Maksymetz J, Byun N, Luessen D, Li B, Barry R, Gore J Cell Rep. 2021; 37(5):109950.

PMID: 34731619 PMC: 8628371. DOI: 10.1016/j.celrep.2021.109950.

References

Lindsley C, Stauffer S . Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012). Pharm Pat Anal. 2013; 2(1):93-108. DOI: 10.4155/ppa.12.82. View

Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L . Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2012; 71(2):489-501. PMC: 3556473. DOI: 10.1007/s00280-012-2040-6. View

Engers D, Lindsley C . Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders. Drug Discov Today Technol. 2013; 10(2):e269-76. PMC: 3779342. DOI: 10.1016/j.ddtec.2012.10.007. View

Tizzano J, Griffey K, Schoepp D . Receptor subtypes linked to metabotropic glutamate receptor agonist-mediated limbic seizures in mice. Ann N Y Acad Sci. 1995; 765:230-5; discussion 248. DOI: 10.1111/j.1749-6632.1995.tb16579.x. View

Rook J, Noetzel M, Pouliot W, Bridges T, Vinson P, Cho H . Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol Psychiatry. 2012; 73(6):501-9. PMC: 3572342. DOI: 10.1016/j.biopsych.2012.09.012. View

Bridges T, Rook J, Noetzel M, Morrison R, Zhou Y, Gogliotti R . Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Drug Metab Dispos. 2013; 41(9):1703-14. PMC: 3876804. DOI: 10.1124/dmd.113.052084. View

Sharma S, Kedrowski J, Rook J, Smith R, Jones C, Rodriguez A . Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. J Med Chem. 2009; 52(14):4103-6. PMC: 3192011. DOI: 10.1021/jm900654c. View

Cho H, Engers D, Venable D, Niswender C, Lindsley C, Conn P . A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors. ACS Chem Neurosci. 2014; 5(7):597-610. PMC: 4102972. DOI: 10.1021/cn5000343. View

Frank R, McRae A, Pocklington A, van de Lagemaat L, Navarro P, Croning M . Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. PLoS One. 2011; 6(4):e19011. PMC: 3084736. DOI: 10.1371/journal.pone.0019011. View

10.

Ngomba R, Santolini I, Biagioni F, Molinaro G, Simonyi A, van Rijn C . Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology. 2011; 60(7-8):1281-91. DOI: 10.1016/j.neuropharm.2011.01.007. View

11.

Rook J, Xiang Z, Lv X, Ghoshal A, Dickerson J, Bridges T . Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Neuron. 2015; 86(4):1029-1040. PMC: 4443790. DOI: 10.1016/j.neuron.2015.03.063. View

12.

Wenthur C, Gentry P, Mathews T, Lindsley C . Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol. 2013; 54:165-84. PMC: 4063350. DOI: 10.1146/annurev-pharmtox-010611-134525. View

13.

Conn P, Lindsley C, Meiler J, Niswender C . Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014; 13(9):692-708. PMC: 4208620. DOI: 10.1038/nrd4308. View

14.

Menniti F, Lindsley C, Conn P, Pandit J, Zagouras P, Volkmann R . Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem. 2013; 13(1):26-54. PMC: 3792577. DOI: 10.2174/1568026611313010005. View

15.

Melancon B, Hopkins C, Wood M, Emmitte K, Niswender C, Christopoulos A . Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem. 2011; 55(4):1445-64. PMC: 3349997. DOI: 10.1021/jm201139r. View

16.

Jones C, Bubser M, Thompson A, Dickerson J, Turle-Lorenzo N, Amalric M . The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2011; 340(2):404-21. PMC: 3263969. DOI: 10.1124/jpet.111.187443. View

17.

Morris L, Nance K, Gentry P, Days E, Weaver C, Niswender C . Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). J Med Chem. 2014; 57(23):10192-7. PMC: 4266362. DOI: 10.1021/jm501375c. View

18.

Byun N, Grannan M, Bubser M, Barry R, Thompson A, Rosanelli J . Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology. 2014; 39(7):1578-93. PMC: 4023154. DOI: 10.1038/npp.2014.2. View

19.

Wood M, Hopkins C, Brogan J, Conn P, Lindsley C . "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry. 2011; 50(13):2403-10. PMC: 3792571. DOI: 10.1021/bi200129s. View

20.

Owen D . Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu₁). ACS Chem Neurosci. 2012; 2(8):394-401. PMC: 3369754. DOI: 10.1021/cn2000124. View